Update on Debt Facility

By

Regulatory News | 31 Jan, 2023

Updated : 23:58

RNS Number : 4749O
Templeton Emerging Markets IT PLC
31 January 2023
 

31 January 2023

Templeton Emerging Markets Investment Trust PLC (the "Company")

Legal Entity Identifier: 5493002NMTB70RZBXO96

 

Amendment and Restatement of Debt Facility

The Company announces that its multicurrency revolving facility agreement with The Bank of Nova Scotia (the "Debt Facility") has been amended and restated pursuant to an amendment and restatement agreement dated 31 January 2023 (the "Amendment and Restatement Agreement").

Pursuant to the Amendment and Restatement Agreement, the maturity date under the Debt Facility has been extended to 30 January 2024. The commitment fee on unutilised commitments has also been amended to a flat fee of 0.4 per cent. per annum. The other material terms of the Debt Facility remain unchanged.

As at the date of this announcement, the Debt Facility is undrawn.

 Paul Manduca, Chairman of the Board commented:

"The Company's gearing policy currently permits debt of up to 20% of net asset value. The Board has decided that renewing the Debt Facility to maintain the flexibility to use gearing when appropriate remains appropriate."

For further information please email temitcosec@franklintempleton.com or contact Client Dealer Services at Franklin Templeton on free phone 0800 305 306, +44 (0) 20 7073 8690 for overseas investors, or e-mail enquiries@franklintempleton.co.uk.

END

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCNKDBPABKDBDN

Last news